Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical study of BIO101 (20-hydroxyecdysone) in obesity.

The study will measure muscle strength, mobility and body composition. It is due to start mid-2024 in the United States and could be extended to Europe.

Biophytis expects preliminary results in 2025 and is seeking funding and partnerships to complete the study.